Entrepreneurship Articles
-
Beyond RAG: When To Use Semantics, Retrieval, Graph, And Agent Inference
10/26/2026
Most large pharmaceutical organizations already own many of the components required for layered architecture. The problem is that these systems often evolve independently.
-
Beyond RAG: Why Life Sciences AI Workflows Need Better Context, Not Just Better Models
10/21/2026
Teams want AI systems that can answer complex scientific questions across value chain, but as these systems move closer to production, a recurring problem is becoming visible.
-
A Quantitative Procurement Framework For Scaling Organ-On-A-Chip Adoption Across Markets Of Varying Maturity
10/16/2026
OoC commercialization is moving beyond technical feasibility toward reproducible, scalable, and economically viable adoption. Achieving this shift requires procurement to move beyond unit-price negotiations.
-
Inside Discovery On Target 2026: New Modalities, AI, And A Higher Funding Bar
10/7/2026
Discovery on Target 2026 showed how new modalities and AI are expanding drug discovery as investors demand stronger data and clearer paths to value.
-
A Procurement Framework For Evaluating Innovation Across Pharma R&D Suppliers
10/7/2026
The patent cliff has changed the mandate of R&D procurement. This paper introduces a 100-point innovation partner assessment framework that scores R&D suppliers.
-
2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics
6/12/2026
Arvin Soepriatna's TEEM Therapeutics is building predictive 3D human heart tissue models to improve cardiac drug screening, reduce risk earlier, and better flag cardiotoxicity.
-
2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics
6/11/2026
Startup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.
-
2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio
6/11/2026
Dr. Chat Jayasuriya discusses EnkaBio’s meniscus repair therapy, fundraising, Nucleate’s impact, CEO search, and tech transfer from Brown/Rhode Island Hospital.
-
2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics
6/10/2026
Chris Clifford, founder of Mimic Therapeutics, describes the company’s mission as protecting cell therapies from immune rejection, with an initial focus on Type 1 diabetes.
-
2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore
6/10/2026
Carlos Ezio, co-founder and CEO of Criocore, a Harvard Medical School spinout developing bioprinted and frozen human tissue models for preclinical development.